Literature DB >> 20231490

Cyclopentenone prostaglandin-induced unfolding and aggregation of the Parkinson disease-associated UCH-L1.

Leonardus M I Koharudin1, Hao Liu, Roberto Di Maio, Ravindra B Kodali, Steven H Graham, Angela M Gronenborn.   

Abstract

Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) has been implicated in Parkinson's disease (PD) and is present in neurofibrillary tangles or Lewy bodies. However, the molecular basis for UCH-L1s involvement in proteinacious fibril formation is still elusive, especially in regard to the pathogenicity of the I93M mutation. Here we show that modification of UCH-L1 by cyclopentenone prostaglandins causes unfolding and aggregation. A single thiol group on Cys152 reacts with the alpha,beta-unsaturated carbonyl center in the cyclopentenone ring of prostaglandins, resulting in a covalent adduct. We also show that the PD-associated I93M mutant of UCH-L1 is well-folded, structurally similar to the wild-type protein, and aggregates upon conjugation by cyclopentenone prostaglandins. Our findings suggest a possible mechanistic link between UCH-L1 modification by cyclopentenone prostaglandins and the etiology of neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20231490      PMCID: PMC2872412          DOI: 10.1073/pnas.1002295107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1.

Authors:  Chittaranjan Das; Quyen Q Hoang; Cheryl A Kreinbring; Sarah J Luchansky; Robin K Meray; Soumya S Ray; Peter T Lansbury; Dagmar Ringe; Gregory A Petsko
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

2.  The ubiquitin pathway in Parkinson's disease.

Authors:  E Leroy; R Boyer; G Auburger; B Leube; G Ulm; E Mezey; G Harta; M J Brownstein; S Jonnalagada; T Chernova; A Dehejia; C Lavedan; T Gasser; P J Steinbach; K D Wilkinson; M H Polymeropoulos
Journal:  Nature       Date:  1998-10-01       Impact factor: 49.962

3.  Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases.

Authors:  C N Larsen; B A Krantz; K D Wilkinson
Journal:  Biochemistry       Date:  1998-03-10       Impact factor: 3.162

4.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

5.  Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease.

Authors:  D M Maraganore; M J Farrer; J A Hardy; S J Lincoln; S K McDonnell; W A Rocca
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

6.  Identification of actin as a 15-deoxy-Delta12,14-prostaglandin J2 target in neuroblastoma cells: mass spectrometric, computational, and functional approaches to investigate the effect on cytoskeletal derangement.

Authors:  Giancarlo Aldini; Marina Carini; Giulio Vistoli; Takahiro Shibata; Yuri Kusano; Luca Gamberoni; Isabella Dalle-Donne; Aldo Milzani; Koji Uchida
Journal:  Biochemistry       Date:  2007-02-13       Impact factor: 3.162

7.  Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases.

Authors:  Joungil Choi; Allan I Levey; Susan T Weintraub; Howard D Rees; Marla Gearing; Lih-Shen Chin; Lian Li
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

8.  15-deoxy-Delta12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-alpha via covalent modification of DNA-binding domain.

Authors:  Han-Jong Kim; Joon-Young Kim; Zhaojing Meng; Li Hua Wang; Fa Liu; Thomas P Conrads; Terrence R Burke; Timothy D Veenstra; William L Farrar
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

9.  Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.

Authors:  Tsuyoshi Waku; Takuma Shiraki; Takuji Oyama; Yoshito Fujimoto; Kanako Maebara; Narutoshi Kamiya; Hisato Jingami; Kosuke Morikawa
Journal:  J Mol Biol       Date:  2008-10-19       Impact factor: 5.469

10.  Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy.

Authors:  Tomohiro Kabuta; Akiko Furuta; Shunsuke Aoki; Koh Furuta; Keiji Wada
Journal:  J Biol Chem       Date:  2008-06-12       Impact factor: 5.157

View more
  30 in total

1.  Targeting of histone acetyltransferase p300 by cyclopentenone prostaglandin Δ(12)-PGJ(2) through covalent binding to Cys(1438).

Authors:  Kodihalli C Ravindra; Vivek Narayan; Gerald H Lushington; Blake R Peterson; K Sandeep Prabhu
Journal:  Chem Res Toxicol       Date:  2011-12-16       Impact factor: 3.739

2.  COX2-derived primary and cyclopentenone prostaglandins are increased after asphyxial cardiac arrest.

Authors:  Hao Liu; Marie E Rose; Tricia M Miller; Wenjin Li; Sunita N Shinde; Alicia M Pickrell; Samuel M Poloyac; Steven H Graham; Robert W Hickey
Journal:  Brain Res       Date:  2013-04-24       Impact factor: 3.252

3.  Protein disulfide isomerase as a novel target for cyclopentenone prostaglandins: implications for hypoxic ischemic injury.

Authors:  Hao Liu; Jie Chen; Wenjin Li; Marie E Rose; Sunita N Shinde; Manimalha Balasubramani; Guy T Uechi; Bülent Mutus; Steven H Graham; Robert W Hickey
Journal:  FEBS J       Date:  2015-03-27       Impact factor: 5.542

4.  Identification of Novel Protein Targets of Dimethyl Fumarate Modification in Neurons and Astrocytes Reveals Actions Independent of Nrf2 Stabilization.

Authors:  Gerardo G Piroli; Allison M Manuel; Tulsi Patel; Michael D Walla; Liang Shi; Scott A Lanci; Jingtian Wang; Ashley Galloway; Pavel I Ortinski; Deanna S Smith; Norma Frizzell
Journal:  Mol Cell Proteomics       Date:  2018-12-26       Impact factor: 5.911

Review 5.  Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia.

Authors:  Steven H Graham; Hao Liu
Journal:  Ageing Res Rev       Date:  2016-10-01       Impact factor: 10.895

6.  Modification of ubiquitin-C-terminal hydrolase-L1 by cyclopentenone prostaglandins exacerbates hypoxic injury.

Authors:  Hao Liu; Wenjin Li; Muzamil Ahmad; Tricia M Miller; Marie E Rose; Samuel M Poloyac; Guy Uechi; Manimalha Balasubramani; Robert W Hickey; Steven H Graham
Journal:  Neurobiol Dis       Date:  2010-10-13       Impact factor: 5.996

Review 7.  Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration.

Authors:  Maria E Figueiredo-Pereira; Chuhyon Corwin; John Babich
Journal:  Ann N Y Acad Sci       Date:  2016-01-08       Impact factor: 5.691

8.  Increased generation of cyclopentenone prostaglandins after brain ischemia and their role in aggregation of ubiquitinated proteins in neurons.

Authors:  Hao Liu; Wenjin Li; Muzamil Ahmad; Marie E Rose; Tricia M Miller; Mei Yu; Jie Chen; Jordan L Pascoe; Samuel M Poloyac; Robert W Hickey; Steven H Graham
Journal:  Neurotox Res       Date:  2013-01-25       Impact factor: 3.911

9.  PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2.

Authors:  Kai-Yvonne Shivers; Anastasia Nikolopoulou; Saima Ishaq Machlovi; Shankar Vallabhajosula; Maria E Figueiredo-Pereira
Journal:  Biochim Biophys Acta       Date:  2014-06-23

10.  Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease.

Authors:  Magdalena J Kiprowska; Anna Stepanova; Dustin R Todaro; Alexander Galkin; Arthur Haas; Scott M Wilson; Maria E Figueiredo-Pereira
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-04-01       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.